Radiotherapy vs Chemotherapy for Prostate Cancer

Palo Alto (17 mi)

Age: 18+

Sex: Male

Travel: May be covered

Time Reimbursement: Varies

Trial Phase: Phase 2

Waitlist Available

Sponsor: Canadian Cancer Trials Group

No Placebo Group

Prior Safety Data

Trial Summary

What is the purpose of this trial?177Lu PSMA 617 is a new type of therapy which is designed to deliver high doses of radiation directly to prostate cancer sites in the body. The purpose of this study is to find out whether 177Lu PSMA 617can slow the growth of prostate cancer compared to standard chemotherapy treatment

Eligibility Criteria

Men over 18 with advanced prostate cancer that's resistant to hormone therapy and has spread, showing progression despite treatment with drugs like abiraterone or enzalutamide. They must have PSMA-positive cancer confirmed by PET imaging, be in fairly good health (ECOG 0-2), and have recovered from previous treatments. Excluded are those who've had certain prior therapies including 177Lu-PSMA, recent major surgery, uncontrolled medical conditions, brain metastases, or severe allergies to study drugs.

Inclusion Criteria

My condition worsened despite treatment with specific prostate cancer medications.

My prostate cancer diagnosis was confirmed by a tissue sample and does not include small cell cancer.

My scans show PSMA positive metastatic disease using specific tracers.

I have had surgery to remove my testicles or I am on hormone therapy with low testosterone levels.

I am a man aged 18 or older.

I am able to care for myself and perform daily activities.

My prostate cancer is spreading despite hormone therapy.

Exclusion Criteria

I have not had major surgery in the last 4 weeks.

I have had radiation on my cancer spots less than 12 weeks ago.

I have brain metastases.

My cancer has large soft tissue lesions not seen on a specific PET scan.

I have a serious heart condition.

Treatment Details

This trial is testing whether a new targeted radiation therapy called 177Lu PSMA-617 can slow the growth of prostate cancer more effectively than the standard chemotherapy drug Docetaxel. Patients will receive either the experimental therapy or standard chemotherapy to compare effectiveness.

2Treatment groups

Experimental Treatment

Active Control

Group I: 177 Lu-PSMA-617Experimental Treatment1 Intervention

Group II: DocetaxelActive Control1 Intervention

177Lu-PSMA-617 is already approved in United States, European Union for the following indications:

🇺🇸 Approved in United States as Pluvicto for: